Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization of USD 682 million, the company faces challenges, including a negative return on equity and no dividend yield, as it navigates the competitive biotechnology sector.
Fulgent Genetics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 23.57 on October 1, 2025. This achievement marks a notable increase from its 52-week low of USD 14.57, reflecting a year-over-year performance of 15.37%.
With a market capitalization of USD 682 million, Fulgent Genetics operates in a competitive industry where it continues to navigate various market dynamics. The company’s financial metrics indicate a challenging environment, as it currently reports a negative return on equity of -2.87% and a debt-to-equity ratio of -0.26. Additionally, the company does not offer a dividend yield, which is consistent with its loss-making status.
As Fulgent Genetics continues to evolve within the biotechnology landscape, its recent price movement underscores the ongoing developments and trends impacting its market position. The stock’s performance relative to the S&P 500, which has seen a 16.09% increase over the same period, highlights the broader market context in which Fulgent operates.